Mizuho Securities Downgrades AcelRx Pharmaceuticals (ACRX) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Cowen Downgrades AcelRx Pharmaceuticals (ACRX) to Neutral
March 10, 2015 11:52 AM EDTCowen downgraded AcelRx Pharmaceuticals (NASDAQ: ACRX) from Outperform to Neutral and removed their $14 price target in light of recent discussions between ACRX and the FDA revealing that an additional clinical trial would be required to resubmit the Zalviso NDA.
"While we believe Zalviso... More
Jefferies Downgrades AcelRx Pharmaceuticals (ACRX) to Hold
March 10, 2015 6:42 AM EDTJefferies downgraded AcelRx Pharmaceuticals (NASDAQ: ACRX) from Buy to Hold with a price target of $6.00 (from $12.00).
Analyst Biren Amin comments, "ACRX has received a letter in which the FDA requests an add'l clinical study to assess the risk of inadvertent dispensing w/... More
